Herpes simplex virus infections Therapeutic Pipeline Projects Vast Growth Ahead

  • Published: May 2017

According to a new research report “Herpes simplex virus infections Therapeutic Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Intelligence, Herpes simplex virus infections Therapeutic pipeline currently exhibits a pipeline with 20 drug candidates.

Access More About This Research at:

Herpes simplex virus infections Therapeutic pipeline in 2017

The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development.

Insights on pipeline segments

As per the findings of the research, most of the drug candidates are being developed to be administered by oral route.

New innovating technologies offer development of promising drugs

Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections. The technologies include, but not limited to, Vector based technology platform, AdenoVerse technology platform, Juvari’s technology platform and Nanostat technology platform.

Major companies collaborate for the development of Herpes simplex virus infections Pipeline

The research found that various companies have collaborated for the development of Herpes simplex virus infections pipeline. In June 2014, PaxVax Inc., entered into a research and development collaboration with the University of California to develop a combination vaccine to prevent genital herpes simplex virus infections.

Some of the key players developing drugs for the treatment of Herpes virus simplex infections include Maruho Co., Ltd., NanoBio Corporation, Lumavita AG and others.

Herpes Simplex Virus Infections Therapeutics Pipeline Analysis

  • By Phase
  • By Route of Administration
  • By Molecule Type
  • By Company